The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Urovant Sciences, a phase 3 biotech developing an acquired oral therapy for overactive bladder, raised $140 million by offering 10 million shares at $14, the low end of the range of $14 to $16. Urovant Sciences plans to list on the Nasdaq under the symbol UROV...read more
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Urovant Sciences, a late-stage biotech developing an acquired oral therapy for overactive bladder, announced terms for its IPO on Monday. The London, United Kingdom-based company plans to raise $150 million by offering 10 million shares at a price range of...read more
US IPO Weekly Recap: 12 IPOs wrap up active third quarter as SurveyMonkey pops 34%
The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Urovant Sciences prices IPO at $14, the low end of the range
Urovant Sciences, a phase 3 biotech developing an acquired oral therapy for overactive bladder, raised $140 million by offering 10 million shares at $14, the low end of the range of $14 to $16. Urovant Sciences plans to list on the Nasdaq under the symbol UROV...read more
US IPO Week Ahead: 13 IPOs close out 3rd quarter with biotechs, China and SurveyMonkey
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO
Urovant Sciences, a late-stage biotech developing an acquired oral therapy for overactive bladder, announced terms for its IPO on Monday. The London, United Kingdom-based company plans to raise $150 million by offering 10 million shares at a price range of...read more